Clinical trials: Fasting Plasma Glucose
Diabetes Mellitus Type 2
Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy
This study is designed to assess the potential difference in Fasting Plasma Glucose (FPG) lowering efficacy between the two DPP-4 inhibitors vildagliptin and sitagliptin, both after a two weeks treatment on top of metformin.
- Trial name
- FPG-VISIT (NCT01398592)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 15 sites in Germany
- Volunteers
- 187 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment
The aim of this study is to evaluate the safety, tolerability, and pharmacokinetics of five ISIS 113715 intravenous dose cohorts in drug-naïve type 2 diabetics.
- Trial name
- NCT00330330
- Testing
- ISIS 113715
- Where
- 10 sites in Poland, Russia
- Volunteers
- 96 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
Primary Objective: To identify a best fasting plasma glucose (FPG) target for Chinese type 2 diabetes patients using insulin glargine which can provide the highest control rate of glycated hemoglobin (HbA1c) < 7%.
- Trial name
- NCT02545842
- Testing
- INSULIN GLARGINE
- Where
- 44 sites in China
- Volunteers
- 947 people
- Sponsor
- Sanofi
Type 2 Diabetes
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus…
- Trial name
- NCT02057172
- Testing
- HM11260C, liraglutide
- Where
- United States
- Volunteers
- 254 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Pharmacological Action
Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
Sitagliptin, through its effects on sensitizing alpha-cell sensitivity to glucose, can initiate counter-regulatory glucagon responses at higher glycemic thresholds, thus reducing the number of clinically apparent hypoglycemic…
- Trial name
- NCT03359590
- Testing
- Sitagliptin 100 mg
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Type 2 Diabetes Mellitus
Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea
The aim of this study is to evaluate the safety, tolerability, and pharmacokinetics of two ISIS 113715 subcutaneous doses (15 mg and 30 mg/day) in combination with oral antidiabetic agents (OAD) versus OAD + placebo in patients…
- Trial name
- NCT00327626
- Testing
- ISIS 113715
- Where
- 5 sites in Israel
- Sponsor
- Ionis Pharmaceuticals, Inc.
Diabetes Mellitus, Type 1
SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1
Primary objective: To compare metabolic control as measured by Blood Glucose (BG) upon arising from bed (7:00 am - 12:00 pm) in type 1 Diabetes mellitus patients who skip the morning meal during treatment with MDI basal/bolus…
- Trial name
- NCT00313937
- Testing
- Insulin glargine
- Where
- Germany
- Volunteers
- 91 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus
The purpose of this study is to investigate clinical efficacy and safety of DLBS 32 in the management of subjects with type-II-diabetes mellitus and to determine the minimal effective dose of DLBS 32 for subjects with…
- Trial name
- NCT01005069
- Testing
- DLBS-32
- Where
- 2 sites in Indonesia
- Volunteers
- 72 people
- Sponsor
- Dexa Medica Group
Pre-diabetes
7-Ketolithocholic Acid in Prediabetes
7-Ketolithocholic Acid, a naturally occurring bile acid, is a novel food currently under investigation for potential metabolic benefits, including glucose-lowering effects.
- Trial name
- NCT07650123
- Testing
- 7-KLCA, Diet and Physical Activity
- Where
- 8 sites in Italy
- Volunteers
- 100 people
- Sponsor
- ICE S.p.A.
Diabetes Mellitus, Type 2
Screening for Early Evidence of Diabetes
This is a pivotal study to determine the accuracy of a new device (SCOUT) in screening persons for pre-diabetes or diabetes. SCOUT will be compared to the standard screening test (Fasting Plasma Glucose), using the Oral Glucose…
- Trial name
- SEED (NCT00614783)
- Where
- 15 sites in United States
- Volunteers
- 3,478 people, healthy volunteers welcome
- Sponsor
- VeraLight, Inc.
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes
The purpose of the study is to evaluate the efficacy and safety of vildagliptin 50 mg bid as an add-on therapy to metformin in Japanese patients with T2DM.
- Trial name
- NCT01497522
- Testing
- Vildagliptin
- Where
- 20 sites in Japan
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin
This study will evaluate the longer-term glycemic effect of two medicines approved for initial treatment of type 2 diabetes. The study consists of a 2 week screening period (2 study visits), followed by an 80 week double-blind…
- Trial name
- NCT00386100
- Testing
- Avandamet 6 mg/1500 mg (ttd), Avandamet 4 mg/1000 mg (ttd), Avandamet 2 mg/500 mg (ttd)
- Where
- 116 sites in United States, Argentina and 7 more
- Volunteers
- 688 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
This study is designed to demonstrate the long-term safety of vildagliptin in patients with type 2 diabetes. This study will study vildagliptin as add-on therapy with metformin, thiazolidinedione, α-glucosidase inhibitor (α-GI)…
- Trial name
- NCT01159249
- Testing
- Vildagliptin
- Where
- 24 sites in Japan
- Volunteers
- 245 people
- Sponsor
- Novartis Pharmaceuticals
Type II Diabetes Mellitus
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady…
- Trial name
- NCT07340320
- Testing
- CX11
- Where
- 48 sites in United States, Poland
- Volunteers
- 240 people
- Sponsor
- Corxel Pharmaceuticals
Type 2 Diabetes Mellitus
Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics
The aim of this study is to examine the effects of ISIS 113715 monotherapy on insulin sensitivity, glucose and lipid metabolism and energy expenditure in subjects with type 2 diabetes mellitus.
- Trial name
- NCT00330200
- Testing
- ISIS 113715
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ionis Pharmaceuticals, Inc.